- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 103 | GlobeNewswire (Europe) | WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 23.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ... | 2 | GlobeNewswire (USA) | ||
| 08.04. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 113 | GlobeNewswire (Europe) | WALTHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 11.03. | Xilio Therapeutics reports Q4 results | 2 | Seeking Alpha | ||
| 11.03. | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.03. | Xilio Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.03. | Xilio advances cancer treatments, secures AbbVie collaboration | 7 | Investing.com | ||
| 11.03. | Xilio Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.03. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results | 146 | GlobeNewswire (Europe) | Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T... ► Artikel lesen | |
| 14.02. | AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn | 10 | PMLiVE | ||
| 13.02. | AbbVie and Xilio to collaborate on antibody-based immunotherapies | 6 | Pharmaceutical Technology | ||
| 12.02. | Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? | 3 | Benzinga.com | ||
| 12.02. | AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal | 12 | FierceBiotech | ||
| 12.02. | AbbVie, Xilio Hook up | 4 | Baystreet.ca | ||
| 12.02. | AbbVie and Xilio Therapeutics announce collaboration and option agreement | 7 | Seeking Alpha | ||
| 12.02. | AbbVie, Xilio Partner To Develop Novel Tumor-Activated Immunotherapies; Stock Up In Pre-market | 11 | RTTNews | ||
| 12.02. | Xilio-Aktien schnellen nach Kooperationsvereinbarung mit AbbVie in die Höhe | 4 | Investing.com Deutsch | ||
| 12.02. | Xilio shares soar on AbbVie collaboration deal | 5 | Investing.com | ||
| 12.02. | AbbVie und Xilio kooperieren bei tumoraktivierten Therapien | 7 | Investing.com Deutsch |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,089 | +5,58 % | XFRA PTN: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPALATIN TECHS DL-... ► Artikel lesen | |
| BIOXXMED | 0,450 | -6,25 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| VIVOSIM LABS | 1,930 | -100,00 % | VivoSim Labs, INC. - 8-K, Current Report | ||
| OCUGEN | 0,600 | +2,81 % | Ocugen: Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200-a Novel Fusion Protein for Diabetic Macular Edema | OCU200 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reportedDosing of the second cohort has been approved MALVERN, Pa., March 18... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| BIO-GATE | 0,765 | +4,79 % | Bio-Gate startet Produkt-Launch für Tierpflege in den USA | Bio-Gate hat die Präsenz im nordamerikanischen Veterinärmarkt ausgebaut. Gemeinsam mit einem internationalen Anbieter bringt Bio-Gate neue Tierpflegeprodukte zur Haut-, Ohr- und Wundbehandlung in die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,648 | +4,18 % | Paukenschlag bei Nel ASA! Kaufchance bei Bayer und Defence Therapeutics Aktie? | Paukenschlag bei Nel ASA. Der Wasserstoff-Spezialist hat über das erste Quartal berichtet: Umsatz und Auftragseingang sinken, während man tief in die roten Zahlen rutscht. Bringt der neue Großaktionär... ► Artikel lesen | |
| VAXART | 0,362 | +5,41 % | Vaxart, Inc.: Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress | Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting as Recommended by Leading Independent Proxy Advisory Firms SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,066 | +6,09 % | Burcon NutraScience Corporation: Burcon Integrates Protein Technologies at Galesburg Facility | Vancouver, British Columbia--(Newsfile Corp. - April 1, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,226 | +4,63 % | Cellectar Biosciences, Inc. - 8-K, Current Report | ||
| AFFIMED | 0,530 | -100,00 % | Affimed N.V.: Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement | MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market | OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ("AIM" or the "Company") (OTC Pink: AIMI) - an immuno-pharma company focused on the research and development of therapeutics to... ► Artikel lesen | |
| IMMUNIC | 0,851 | -2,18 % | EQS-News: Immunic AG: Immunic to Participate in Scientific and Industry Conferences in May | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Scientific and Industry Conferences in May
02.05.2025 / 12:30 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,145 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| CEL-SCI | 0,216 | +1,51 % | CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer | VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments.
"We... ► Artikel lesen |
Das Unternehmen XILIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,667 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.